Inventor · Foster City, CA, US

Lei Ling

37Patents
15h-index
16Co-inventors
78Inventor score

Filing activity: Jan 11, 2000 → Oct 11, 2019

Most-cited inventions

PatentTitleAreaCited byStatus
US8951966B2 Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases Physics 55 Active
US9089525B1 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject Physics 37 Active
US9580483B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes Physics 36 Active
US9290557B2 Compositions comprising variants and fusions of FGF19 polypeptides Chemistry; Metallurgy 36 Active
US9273107B2 Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases Physics 36 Active
US9670260B2 Compositions comprising fusion variants of FGF19 polypeptides Physics 33 Active
US9751924B2 Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject Physics 32 Active
US9889178B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis Physics 25 Active
US9895416B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis Physics 25 Active
US9878009B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis Physics 25 Active
US9925242B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis Physics 25 Active
US9889177B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis Physics 25 Active
US9878008B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption Physics 25 Active
US9974833B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis Physics 19 Active
US9963494B2 Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject Physics 19 Active
US10413590B2 Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject Physics 10 Active
US10456449B2 Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases Chemistry; Metallurgy 9 Active
US10369199B2 Methods of using variants of FGF19 polypeptides for the treatment of cancer Physics 9 Active
US10398758B2 Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions Physics 9 Active
US6432454B1 Processes of making north american ginseng fractions, products containing them, and use as immunomodulators Human Necessities 8 Expired
US7195783B2 Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics Human Necessities 7 Expired
US10744185B2 Methods of using variants of FGF19 polypeptides for the treatment of pruritus Human Necessities 7 Active
US7056685B1 Receptor ligands and methods of modulating receptors Emerging Cross-Sectional Technologies 4 Expired
US7186423B2 Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators Human Necessities 4 Expired
US7413756B2 Processes of making north american ginseng fractions, products containing them, and use as immunomodulators Human Necessities 3 Expired

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.